Citations

Clear

6273 citation(s) found for "To, Andrew".

Radiomic Parenchymal Phenotypes of Breast Texture from Mammography and Association with Risk of Breast Cancer
Winham, Stacey J. , Scott, Christopher G. , Gastounioti, Aimilia , Horng, Hannah , Norman, Aaron D. , Mankowski, Walter C. , Pantalone, Lauren , Jensen, Matthew R. , Acciavatti, Raymond J. , Cohen, Eric A. , Brandt, Kathleen R. , Vachon, Celine M. , Scott, Christopher , Gastounioti, Aimilia , Horng, Hannah , Norman, Aaron D , Mankowski, Walter C , Jensen, Matthew R , Acciavatti, Raymond J , Maidment, Andrew D A , Brandt, Kathleen R , Conant, Emily F , Kerlikowske, Karla M , Kontos, Despina , Vachon, Celine M. , Winham, Stacey J , McCarthy, Anne Marie , Maidment, Andrew D. A. , Conant, Emily F. , Kerlikowske, Karla

Mayo Clinic

Radiology | May 13, 2025 | Volume: 315 | Issue: 2 | Pages: No page available

10.1148/radiol.240281 | PMID 40358450 Get It

Radiomic parenchymal phenotypes on mammograms were used to predict breast cancer risk among both Black and White women, notably for false-negative findings and symptomatic interval cancer.
Harmonized Assessment and Quality Control of Quantitative Measures of Lung Structure on Pre-pandemic Cardiac and Lung Computed Tomography (CT) Scans for Large-scale Investigation of Risk of Long COVID-19: The Collaborative Cohort of Cohorts for COVID-19 Re
Naik, Seema , Smith, B.M. , Cheng, T.-K., Lynch, David A. , Matsushita, Kunihiro , O'Driscoll, O., Ortega, Victor E. , Washko, George R. , Laine, Andrew F. , Oelsner, Elizabeth C. , Oelsner, Elizabeth C , Naik, S., Allen, Norrina B. , Balte, Pallavi , Blaha, Michael Joseph , Budoff, Matthew J. , Carr, J. Jeffrey , Carson, April P. , Cheng, T.-K., Estépar, Raúl San Jośe , Hoffman, Eric A. , Humphries, Stephen M. , Kanaya, Alka M , Kandula, Namratha R. , O’Connor, George T. , Pottinger, Tess D. , Schwartz, David A. , Wenzel, Sally E. , Xanthakis, Vanessa , Angelini, Elsa D. , Barr, R. Graham

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A7658-A7658

10.1164/ajrccm.2025.211.abstracts.a7658 Get It

Abstract RATIONALE: Susceptibility to severe COVID-19 and long COVID may be influenced by pre-existing lung structure. ECG-gated, non-contrast cardiac CT scans, originally acquired for assessing coronary artery calcium, are available in multiple longitudinal cohort studies and have been previously validated against lung CT scans for densitometry; however, protocol variation across cohorts may hinder direct comparison. To address this, we developed a quality control (QC) rubric to grade cardiac CT scans for standardized quantitative lung measures across cohorts. METHODS: C4R assessed SARS-CoV-2 infection and outcomes in 14 NHLBI cohorts, of which 10 (six community-based and four longitudinal case-control studies) included CT scans (12,459 participants with lung and 13,752 with cardiac CTs). Logic rules were applied to categorize scans (Table): Grade “A-B” scans had 2-3.5mm slice thickness, at least 20 axial slices, no lung cropping in axial view and lung and airway volumes greater than the cohort-specific 1st percentile. “C-D” scans had one lung obscured by cropping around the heart, so quantitative measures were restricted to the lung in complete view. “F-H” scans were deemed unusable, suffering from low slice count (<20), severe image cropping, low lung or airway volumes (< 1st%ile). Visual inspection was performed on a sample from each category to ensure accuracy. Percent of lung voxels in low attenuation areas < -950 HU (LAA950), high attenuation areas (-600 to -250 HU, HAA) and 15th percentile HU value (perc15) were measured. Within-participant variability was quantified using the intraclass correlation coefficient (ICC). RESULTS: We performed QC on cardiac CT scans from an initial sample of 6,275 participants from three C4R cohorts (ARIC, CARDIA, MASALA), imaged with GE or Siemens scanners. Of these, 5,125 (81.7%) were graded “A-B”, 496 (7.9%) were “C-D” and 654 (10.4%) were “F-H”. The percentage of “F-H” scans varied widely across cohorts [<1% to 26%] due to image cropping. Among the 5,621 cardiac CT scans graded A-D, the mean±SD for LAA950, HAA and perc15 respectively were 1.1±2.1%, 7.2±4.7% and -887±33 HU. Repeated imaging was available for 107 participants (time interval 5.1±0.7y). For paired scans in grades A-B (n=101/107), the within-participant correlation for LAA950, HAA and perc15 were 0.91, 0.38 and 0.74 respectively. CONCLUSION: Initial application of QC to cardiac CT scans identified scans with high reproducibility, with the aim to provide valid quantitative lung metrics on over 20,000 highly characterized participants in C4R.
Male Survival Disadvantage in Pulmonary Hypertension in the PVRI Godeep Meta-registry
Annis, Jeffrey , Meike, F., Wilhelm, Jochen , Kiely, David G. , Balasubramanian, A., Eichstaedt, Christina A. , Zamanian, Roham T. , Elwing, Jean , Pepke-Zaba, J., Hernandez, Nadia , Frauendorf, Marlize , Williams, Paul , Anthi, Anastasia , Dima, Efrossini, Majeed, Rehan, Tello, Khodr , Kiely, David , Yogeswaran, Athiththan , Howard, Luke , Lawrie, Allan , Wilkins, Martin R. , Balasubramanian, A. , Hassoun, Paul M. , Grünig, Ekkehard , Sweatt, Andrew J. , Kovács, Gábor , Olschewski, Horst , Ghouleh, Imad Al , Chan, Stephen Y. , Jose, Arun , Cannon, J., Pepke-Zaba, J., Frantz, Robert P. , Sіrenko, Yu.M. , Torbas, O.O. , Sahay, Sandeep , Hernandez, N., Arvanitaki, Alexandra , Giannakoulas, George , Sabbour, Hani Mohamed , Saleh, Khaled Musa Mohammad , Ghio, Stefano , Scelsi, Laura , Majeed, R., Ghofrani, Hossein Ardeschir , Grimminger, Friedrich , Cajigas, Héctor , Brittain, Evan L , Seeger, Werner

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A7097-A7097

10.1164/ajrccm.2025.211.abstracts.a7097 Get It

Abstract Introduction Sex-based differences in morbidity and mortality for pulmonary hypertension (PH) are insufficiently addressed in current research. However, recognizing these differences is crucial for optimal clinical management and improving outcomes. This study assesses the effect of sex on survival among PH patients, while accounting for disease severity, comorbidities, treatment, and race. Methods We analyzed data from the PVRI GoDeep meta-registry, including all incident patients with complete hemodynamic profiles. Survival was evaluated using Kaplan-Meier and Cox proportional hazards models, adjusted for various confounders. Analyses included both PAH and non-PAH groups and risk assessment by the ESC/ERS 2022, REVEAL lite 2, and COMPERA 4-strata scores. All analyses were performed using R (The R Foundation). Results A total of 19,663 incident PH patients were included in the analysis, with 5,581 patients (28%) diagnosed with Group 1 PH and a median age of 64 years [IQR: 52-73]. Among these, male patients (8,704, 44%) had a significantly higher mortality risk than female patients across the entire cohort and within all PH subtypes. The adjusted hazard ratio for mortality in male versus female patients was 1.391 [95% CI: 1.260-1.536] in the overall population and 1.404 [95% CI: 1.264-1.561] for those with PAH. This survival difference was consistent across various severity levels, age groups, and in the presence of comorbidities such as obesity and cardiovascular diseases, as well as among those receiving PAH-specific therapies as well as patients who remained without treatment during the observation period. Notably, male disadvantage in survival was observed in low, intermediate, and high-risk categories for ESC/ERS 2022, REVEAL lite 2, and COMPERA scores but not within REVEAL 2.0, which includes male sex as a non-modifiable risk factor. Racial analysis revealed a greater mortality risk for males among White patients, with no significant differences noted in Black or Asian populations. Conclusion Our PVRI GoDeep meta-registry analysis demonstrates that male PH patients face higher mortality risk across both PAH and non-PAH groups, independent of disease etiology, age, severity, comorbidities, and treatment factors, with this risk amplified in White patients. These findings suggest that male sex should be further considered as a risk factor to refine predictive models for survival in PH.
Proteomics of CT Emphysema Subtypes in the General Population. The Multi-Ethnic Study of Atherosclerosis (MESA) Lung Study
Guzman, Daniel E., Sun, Yifei , Bertoni, Alan, Johnson, W. Craig , Watson, Karol E., Hoffman, E.A., Dubin, Robert , Oelsner, Elizabeth C. , Laine, Andrew F. , Ortega, Victor E. , Oelsner, Elizabeth C , Pottinger, Tess D. , Post, Wendy S. , Allen, Norrina B. , Pankow, James S. , Manichaikul, Ani , Dubin, R., Deo, Rajat , Angelini, Elsa D. , Bowler, Russell P. , Ganz, Peter , Barr, R. Graham

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A5009-A5009

10.1164/ajrccm.2025.211.abstracts.a5009 Get It

Abstract Chronic obstructive pulmonary disease (COPD) and pulmonary emphysema were the third-leading cause of death globally in 2019. Besides alpha-1 antitrypsin deficiency, emphysema lacks disease-modifying medications due to its heterogeneity and there remains a need to further investigate emphysema subtypes to advance its diagnosis and treatment. Recent unsupervised machine learning of the texture and anatomical location of emphysema on computed tomography (CT) images of the lung defined six quantitative CT emphysema subtypes uniquely associated with specific gene variants, environmental exposures, symptoms, physiology and clinical events. We aim to identify associations of plasma proteins with each CT emphysema subtype cross-sectionally in a multi-ethnic general population sample. MESA is a prospective cohort study that recruited 6,814 participants from six communities who self-identified as White, Black, Hispanic, or Asian race/ethnicity, ages 45-84 years old and free of clinical cardiovascular disease in 2000-02. The MESA Lung Study performed CT scans among 3,137 participants in 2010-12, which were labeled with previously described (PMID: 37268414) CT emphysema subtypes. Proteomics was assessed using SomaScan version 4.1 assay (7,596 plasma proteins). Linear regression models were adjusted for age, height, weight, sex, race, educational attainment, smoking status, pack years, urine cotinine level, body-mass index (BMI), estimated glomerular filtration rate (eGFR), CT scanner manufacturer and other CT emphysema subtypes. Results were adjusted to reflect a False Discovery Rate (FDR) p-value of less than 5% using the Benjamini-Hochberg method. Among 2,343 participants with both CT and proteomic data (mean age 69.5 years, 52.3% women, 23.7% with COPD), we identified statistically significant associations of proteins with the vanishing lung subtype (42 proteins; top hit Natural cytotoxicity triggering receptor 3 ligand 1, q = 2.9[asterisk]10-9), restrictive combined pulmonary fibrosis/emphysema (CPFE) subtype (11 proteins; top hit Integrin alpha-2/b1, q=1.0[asterisk]10-5), the combined bronchitis-apical emphysema subtype (9 proteins; top hit Desmoglein-2, q=8.8[asterisk]10-13), and the diffuse emphysema subtype (4 proteins; top hit Pulmonary surfactant-associated protein D, q=5.7[asterisk]10-3). No significant proteins were associated with the obstructive CPFE or senile subtypes after FDR correction. Most proteins were uniquely associated with one CT emphysema subtype, while a few proteins were associated with more than one subtype. This study identified specific proteins for different CT emphysema subtypes, many of which have been related less specifically to emphysema, including pulmonary surfactant production, anti-inflammatory pathways, and mitochondrial deregulation, amongst others. Validation of these proteomic associations can provide insight into further pathway assessment, clinical biomarker discovery, and targeted prevention of emphysema in the general population.
Inhibition of Candida Auris Phosphoglucomutase – A Novel Therapeutic Target
Barwatt, J.W., Pellegrino, Madeline R., Barwatt, Joseph , Kottom, Theodore J. , Limper, Andrew H.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A3715-A3715

10.1164/ajrccm.2025.211.abstracts.a3715 Get It

Abstract INTRODUCTION Candida auris has emerged as a global pathogenic yeast that disproportionately affects patients in healthcare settings. Infection ranges from localized skin infections to severe bloodstream infections. Multidrug resistance, hardiness on environmental surfaces, and the ability to persist as a colonizer in both sick and healthy patients enables it to spread rapidly in healthcare settings leading to significant morbidity and mortality. Multidrug resistance has led to limited effective therapies and necessitates the need for novel therapeutic options. Here we evaluate the efficacy of ISFP10, an antifungal compound with a novel mechanism of action, against C. auris. ISFP10 inhibits fungal phosphoglucomutase (PGM), an enzyme required for production of substrates for fungal cell wall synthesis (Figure 1). METHODSMIC Testing The compound ISFP10 was submitted to the National Institute of Allergy and Infectious Diseases Therapeutic Development Services for half-maximal and maximal inhibitory concentration (IC50/IC100) testing. C. auris isolates were tested using typical drug-dilution methods. Saccharomyces cerevisiae – C. auris PGM Growth Curve Testing This proof of mechanism assay was instituted to isolate PGM in Saccharomyces for growth curve testing. The Candida auris PGM was cloned into pYES2.1 downstream of an inducible galactose promoter. This plasmid was transformed into S. cerevisiae. C. auris PGM plasmid-containing S. cerevisiae was incubated for 24 hours in 2% glucose minimal media. Using absorbance readings, the inoculum was normalized to 5x105 cells/mL in galactose-containing media. The inoculum was plated onto a 96-well plate in a drug-dilution scheme with ISFP10 at concentrations ranging from 200uM to 6.25uM along with DMSO control wells. Plates were incubated at 30° C for 72 hours in a spectrophotometer with absorbance readings every hour. Growth curves were plotted using GraphPad Prism software. RESULTS The half-maximal inhibitory concentrations (IC50) and maximal inhibitory concentrations (IC100) were consistently low across the three C. auris isolates. The IC50 ranged from 0.5 µg/mL to 1.0 µg/mL, while the IC100 was 1.0 µg/mL for each of the three isolates (Table 1). Growth curves demonstrated concentration-dependent inhibition of C. auris PGM plasmid-containing S. cerevisiae. Figure 2 shows full inhibition of fungal growth at 25µM with dose-dependent delayed growth at lower concentrations. CONCLUSIONS ISFP10 shows promise for inhibiting C. auris PGM in a dose-dependent pattern. It's high in vitro activity and novel mechanism of action necessitates further investigation as a potential therapeutic for C. auris.
Clinical Outcomes of Patients With Idiopathic or Lymphocytic Hypereosinophilic Syndrome in the United States: A Real-world Retrospective Observational Cohort Study
Pongdee, Thanai , Dolin, P., Ding, Bo , Rowell, Jennifer , Edmonds, Carl, Eudicone, James M. , Moore, Andrew M. , Peer, Thomas , Chen, S.Y., Dolin, P., Jain, Priya Narayanan , Edmonds, C., Moore, A.M., Peer, T., Chan, K. Arnold

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A3201-A3201

10.1164/ajrccm.2025.211.abstracts.a3201 Get It

Abstract RATIONALE: Hypereosinophilic syndrome (HES) is a group of rare diseases characterized by persistent hypereosinophilia causing organ damage/dysfunction. Idiopathic and lymphocytic HES (I-HES/L-HES) subgroups exclude clonal and reactive HES. We evaluated real-world clinical outcomes of patients with I-HES/L-HES. METHODS: This retrospective observational cohort study of patients with I-HES/L-HES collected data from the TriNetX Linked Network of de-identified Electronic Health Records plus Claims in the US. Patients had a HES diagnosis (ICD-10-CM: D72.11) between 10/01/2020–09/12/2023, with ≥12 months continuous enrollment before their first HES diagnosis record (index date [ID]). Patients with myeloproliferative/reactive HES, or a diagnosis of eosinophilic granulomatosis with polyangiitis after HES diagnosis, were excluded. Baseline was defined as 12 months prior to ID. Year 1 was defined as 12 months after ID. Patients were followed up until either 09/12/2023, disenrollment from insurance, death, or 24 months after ID, whichever came first. Clinical response was defined as ≥3 months without HES symptoms and a blood eosinophil (bEOS) count ≤750 cells/µL. Complete hematological remission was defined as a bEOS count ≤500 cells/µL. Partial remission was defined as a bEOS count <50% of baseline value, but >500 cells/µL. Kaplan-Meier curves estimated time to first HES flare and hematological remission. Analyses were descriptive. RESULTS: At ID, patients with I-HES/L-HES (N=110) had a mean (standard deviation [SD]) age of 43.8 (21.3) years; 66 (60.0%) were male, 58 (52.7%) were White and 30 (27.3%) were Black or African American. Mean (SD) follow-up was 15.1 (7.7) months. Median (95% confidence interval [CI]) time from ID to first flare (n=47) was 18.0 (11.0, not estimated) months (Table 1). Median (95% CI) time to first complete or partial hematological remission (n=52) was 15.3 (10.8, 21.6) months. The proportion of patients with a definite or probable HES flare was lower at Year 1 (10/69 [14.5%]) versus baseline (40/110 [36.4%]). Few patients achieved clinical response at baseline (10/110 [9.1%]) and Year 1 (5/69 [7.2%]). Among patients with bEOS data, mean (SD) bEOS count was 2235.3 (4351.7) cells/µL at baseline (n=51) and 833.6 (1396.0) cells/µL at Year 1 (n=11). The proportion of patients with a bEOS count <500 cells/µL was 20/51 (39.2%) at baseline and 7/11 (63.6%) at Year 1. CONCLUSION: Despite a reduced proportion of patients experiencing flares within a year after diagnosis, many did not experience hematological remission or clinical response by Year 1; suggesting high disease burden with existing treatment and the need for novel therapies to better manage I-HES/L-HES.
Pulmonary Arterial Hypertension in Octogenarians: The Pulmonary Hypertension Association Registry
Moutchia, Jude , Runo, James , Badesch, D.B., Moss, James , Burger, C.D., Marco, Teresa De , Horn, E., Kawut, S.M., Moss, John E. , Reddy, Raju M , Ravichandran, Ashwin Kumar , Horn, Evelyn M. , Ataya, Ali , Bryant, Andrew J. , Al‐Naamani, Nadine , Kawut, S.M.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A2150-A2150

10.1164/ajrccm.2025.211.abstracts.a2150 Get It

Abstract Rationale: Since the initial descriptions of pulmonary arterial hypertension (PAH), there has been a significant increase in PAH diagnoses among the geriatric population. Studies suggest that older PAH patients exhibit unique hemodynamic profiles and treatment responses. We hypothesized that patients ≥80 years old would have a unique clinical profile and worse outcomes. Methods: The Pulmonary Hypertension Association Registry (PHAR) is a prospective cohort of PAH and chronic thromboembolic pulmonary hypertension (CTEPH) patients new to care at a Pulmonary Hypertension Care Center in the US. Individuals <18 years of age and those with CTEPH were excluded. Clinical data, quality of life measures, and functional capacity were recorded at time of enrollment and at follow up visits. Octogenarians were defined as those ≥80 years old and non-octogenarians as <80 years old. Associations between age subgroups with the change in six-minute walk distance (6MWD), and worsened WHO functional class (WHO FC) at the next visit, and time to all-cause mortality were assessed using linear, binomial, and Cox regression, respectively. Results: The study sample included 87 PAH octogenarian patients and 2,583 non-octogenarian patients at enrollment. The Table shows that octogenarian PAH patients were of similar sex and race distribution as others, but had lower body mass index. Octogenarians were more likely to have idiopathic or CTD-related PAH, and differed from younger patients in terms of several sociodemographic variables. PAH treatment, WHO FC, quality of life, and hemodynamic also differed between the groups. Octogenarians had a lower change in 6MWD (-26m, 95%CI -52 – -2, p = 0.066) and worse WHO FC (2.0, 95%CI 1.1 – 3.8, p = 0.038) over time compared to other adults after adjustment for sex, BMI, PAH etiology, annual income, marital status, right atrial pressure, mean pulmonary artery pressure, and PAH treatment. Octogenarians had an increased risk of death compared to younger adults (hazard ratio 1.7, 95%CI 1.1 – 2.6, p = 0.022) after adjustment for covariates. Conclusions: While the eldest PAH patients may have some comparable features to younger patients, they are different in a variety of socioeconomic variables, disease type, hemodynamics, and number of PAH therapies. The eldest PAH patients demonstrate worse exercise and functional capacity with time and a 70% increased risk of death compared to younger patients. Further studies are needed to better characterize PAH in the elderly, as this may lead to more effective treatments and enhanced quality of life.
Lung Function Improvement in Patients With Uncontrolled, Moderate-to-Severe Asthma Treated With Benralizumab: A New, Retrospective Analysis of the Pooled Sirocco and Calima Studies
Carstens, Donna, Harrison, Andrew , Meyers, Deborah A. , Cohen, David , Koury, Jason , Bleecker, Eugene R. , Koury, J., Menzies-Gow, Andrew N

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A1052-A1052

10.1164/ajrccm.2025.211.abstracts.a1052 Get It

Abstract RATIONALE: Airway remodeling, a key characteristic of severe asthma, leads to progressive loss of lung function and incomplete reversibility of airflow obstruction. We examined the effect of benralizumab on lung function in patients from the pooled SIROCCO (Bleecker ER, et al. Lancet 2016; PMID: 27609408) and CALIMA (FitzGerald JM, et al. Lancet 2016; PMID: 27609406) studies, utilizing a new analysis of spirometry to highlight important changes in forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC) throughout the studies. METHODS: This retrospective analysis pooled data from the randomized, placebo-controlled, double-blind Phase 3 SIROCCO and CALIMA studies. SIROCCO enrolled patients with severe asthma, while CALIMA enrolled patients with moderate-to-severe asthma, both with a planned 2:1 randomization for baseline blood eosinophils ≥300 cells/μL versus <300 cells/μL. All patients (aged 12-75 years) had ≥2 exacerbations in the previous year, despite use of medium- to high-dose inhaled corticosteroids plus additional controllers. Patients in this analysis received subcutaneous benralizumab 30 mg every 8 weeks (Q8W; first three doses given every 4 weeks) for 48 weeks in SIROCCO and 56 weeks in CALIMA. The changes in FEV1 and FVC following bronchodilator (BD) were measured at baseline and study end. Effects on FEV1 and FVC were further stratified by baseline eosinophil count (≥300 cells/μL or <300 cells/μL). Results are reported as mean (standard deviation). RESULTS: Overall, 839 patients received benralizumab Q8W; 557 had a baseline eosinophil count of ≥300 cells/μL and 282 had <300 cells/μL. At baseline, pre- and post-BD FEV1 were 1722 mL (615; n=837) and 2128 mL (755; n=813). At study end, pre- and post-BD FEV1 were 2029 mL (756; n=735) and 2225 mL (800; n=738). At baseline, pre- and post-BD FVC were 2865 mL (905; n=837) and 3285 mL (971; n=813). At study end, pre- and post-BD FVC were 3214 mL (1010; n=735) and 3379 mL (1021; n=738). Pre-BD FEV1 and FVC improved by 307 mL and 349 mL and post-BD FEV1 and FVC improved by 97 mL and 94 mL between baseline and study end, respectively. Stratified by baseline eosinophil count, findings were similar in both groups (Figure). CONCLUSIONS: Benralizumab treatment resulted in both improved FEV1 and FVC while maintaining BD response in patients with uncontrolled, moderate-to-severe asthma. Improvements were seen in patients with baseline eosinophil counts of both ≥300 cells/μL and <300 cells/μL. These results may reflect reduced hyperinflation, potentially due to improved airway inflammation and mucus plugging.
Learned high resolution energy‐integrating detector CT angiography: Harnessing the power of ultra‐high‐resolution photon counting detector CT
Koons, Emily K. , Chang, Shaojie , Missert, Andrew D., Gong, Hao , Thorne, Jamison E. , Hoodeshenas, Safa , McCollough, C, Leng, Shuai, Rajiah, Prabhakar Shantha, Missert, Andrew D., Rajiah, Prabhakar , Leng, Shuai

Mayo Clinic

Medical Physics | May 8, 2025 | Volume: 52 | Issue: 7 | Pages: No page available

10.1002/mp.17874 | PMID 40344194 Get It

Abstract Background Coronary computed tomography angiography (cCTA) is a widely used noninvasive diagnostic exam to assess patients for coronary artery disease (CAD). However, the spatial resolution of most CT scanners is limited due to the use of energy‐integrating detectors (EIDs). Purpose To develop a convolutional neural network ( I mproved LUMEN visualization through A rtificial super‐resolu T ion imag E s (ILUMENATE)) informed by photon‐counting‐detector (PCD)‐CT to improve EID‐CT image resolution and determine its impact on cCTA. Materials and methods With IRB approval, 30 patients undergoing clinically indicated cCTA were scanned with EID‐CT (SOMATOM Force, Siemens Healthineers, Forchheim, Germany) and subsequently with ultra‐high‐resolution (UHR) PCD‐CT (NAEOTOM Alpha, Siemens Healthineers) on the same day. ILUMENATE was trained on eight patient PCD‐CT datasets (67,890 patch pairs with 90% for training (61,101), 10% reserved for validation (6,789)) and applied to 22 unseen EID‐CT cases. Spatial resolution was evaluated using line profiles and percent diameter stenosis quantified with a severity score assigned. Two experienced radiologists, blinded to image type, selected preferred series and scored images for overall quality, sharpness, and noise comparing original EID‐CT and ILUMENATE output. Results Visual assessment and line profiles showed substantial resolution improvement with ILUMENATE. Percent diameter stenosis was significantly reduced (mean ± standard deviation: 4.42% ± 4.82%) using ILUMENATE ( p < 0.001) with nine lesions shifting down in severity score. Readers preferred ILUMENATE images in 22/22 cases and scored ILUMENATE superiorly for overall quality, sharpness, and noise ( p < 0.05). Conclusions ILUMENATE enhanced image resolution, resulting in improved overall image quality, reduced calcium blooming artifacts, and improved lumen visibility in cCTA exams performed using EID‐CT. This could potentially allow for improved accessibility to UHR image quality, allowing for more accurate assessment of CAD.
Efficacy and Morbidity of Heparin Infusion in Salvaging Autologous Breast Reconstruction Free Flaps
Odorico, Scott K. , Mazroua, Muhammad S., Wang, Leda, Day, Serena, Harless, Christin A., Martinez‐Jorge, Jorys, Vijayasekaran, Aparna , Mazroua, Muhammad Sabry, Awadallah, Andrew , Harless, Christin, Martinez-Jorge, Jorys, Awadallah, Andrew S. , Day, Serena J.

Mayo Clinic

Microsurgery | May 8, 2025 | Volume: 45 | Issue: 4 | Pages: No page available

10.1002/micr.70065 | PMID 40341693 Get It

ABSTRACT Background Abdominal‐based free flaps are the mainstay in autologous breast reconstruction. Their safety and consistency in outcomes are well‐documented. When flap compromise occurs, operative salvage is the gold standard. However, when—and if—to place these patients on heparin infusions is unclear. The goal of this study was to investigate abdominal‐based free flap compromise and compare outcomes with and without heparin infusion. Materials and Methods This was a single‐institution, multiple‐surgeon, retrospective chart review of patients undergoing autologous, abdominal‐based free flap breast reconstruction who experienced anastomotic compromise within a 6‐year period. Treatment and outcomes data collected include flap salvage, hematoma, seroma, surgical site infection (SSI), transfusion requirement, and length of hospital stay. Results Fifty‐one flaps had evidence of compromise. A total of 31 (60.8%) patients were placed on heparin infusions after experiencing anastomotic compromise, compared to 20 who did not receive heparin infusion. Thirty‐five patients (68.6%) underwent deep inferior epigastric perforator flaps. Twenty‐six patients (51%) experienced venous congestion, 22 patients (43.1%) experienced arterial compromise, and three (5.9%) experienced both. Twenty‐eight patients (54.9%) received tissue plasminogen activator; in the heparin infusion group, 21 patients (67.7%) received tissue plasminogen activator. The total salvage rate of compromised flaps was 94.1% (48/51). There was no significant difference between heparin infusion and standard cares in length of hospital stay, length of drains in‐place, successful salvage (93.5% vs. 95%), hematoma (19.4% vs. 15%), fat necrosis, SSI, hospital readmission (19.4% vs. 15%), and return rates to the operating room (48.4% vs. 50%). However, there was a significantly higher transfusion rate in patients receiving heparin infusion (38.7% vs. 10%). Of the 25 flaps with evidence of thrombosis, 72% were placed on heparin infusions while 28% were not; there was no significant difference in salvage rate in this sub‐group. Conclusions This review of autologous breast reconstruction free flap compromise provides evidence of similar safety profiles, with similar salvage rates, when comparing salvage with and without heparin infusion; there is a higher transfusion requirement when treating with heparin infusion.